Journal Article

Long-term outcomes after discontinuing biological drugs and tofacitinib in patients with rheumatoid arthritis: A prospective cohort study

Koga, Tomohiro, Ueki, Yukitaka, Okada, Akitomo, Mori, Shunsuke

2022

Overview

This study examined long-term outcomes of biological disease-modifying antirheumatic drugs (bDMARDs) and tofacitinib discontinuation in patients with rheumatoid arthritis (RA). Ninety-seven RA patients who desired drug discontinuation after sustained remission or low disease activity for at least 48 weeks due to stable treatment with biological drugs or tofacitinib were enrolled into this study. All patients were prospectively followed until disease flare or the end of the study. Discontinued drugs (previous drugs) were reintroduced to treat flares. Following bDMARD/tofacitinib discontinuation (mean follow-up, 2.1 years; standard deviation, 2.0), disease flare occurred at a crude incidence rate of 0.36 per person-year. The median time to flare was 1.6 years (95% confidence interval [CI] 0.9-2.6), and the cumulative flare probability was estimated to be 45% at 1 year, 64% at 3 years, and 80% at 5 years. No or little radiological progression was shown in 87.1% of patients who maintained remission for 3 years. A Fine-Gray competing risk regression analysis showed that predictive factors for a flare were longer RA duration at the start of bDMARD/tofacitinib treatment, previous failure of treatment with bDMARDs, and a shorter period of remission or low disease activity before drug discontinuation. Type of discontinued drug was not identified as a predictive factor after adjusting for other predictor variables. Restarting previous treatment regimens led to rapidly regaining disease control in 89% of flare patients within 1 month. Discontinuation of bDMARD/tofacitinib may be a feasible strategy in RA patients, especially patients with early treated and longer-controlled RA. Flares are manageable in most RA patients and radiological progression is rare for at least 3 years in patients with sustained remission after bDMARD/tofacitinib discontinuation.

• Publisher: Public Library of Science,Public Library of Science (PLoS)
• Subject: Antiarthritic agents / Arthritis / Autoimmune diseases / Biological products / Biology and Life Sciences / Cohort analysis / Complications and side effects / Confidence intervals / Disease control / Drug dosages / Drug therapy / Drugs / Flares / Health risks / Medicine and Health Sciences / Observational studies / Patient outcomes / Patients / Physical Sciences / Regression analysis / Remission / Remission (Medicine) / Research and Analysis Methods / Restarting / Rheumatoid arthritis / Rheumatology / Risk analysis / Statistical analysis / Tumor necrosis factor-TNF / Values